Helen Torley - Feb 16, 2023 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
PRESIDENT AND CEO, Director
Signature
/s/ James R. Oehler, Attorney-in-Fact
Stock symbol
HALO
Transactions as of
Feb 16, 2023
Transactions value $
-$544,865
Form type
4
Date filed
2/21/2023, 05:59 PM
Previous filing
Feb 17, 2023
Next filing
Mar 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Options Exercise $0 +21K +3.37% $0.00 645K Feb 16, 2023 Direct
transaction HALO Common Stock Sale -$545K -11.1K -1.72% $49.26 634K Feb 16, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Restricted Stock Units Options Exercise $0 -21K -25% $0.00 63K Feb 16, 2023 Common Stock 21K $0.00 Direct F2
transaction HALO Option to Purchase Common Stock Award $0 +193K $0.00 193K Feb 16, 2023 Common Stock 193K $49.26 Direct F3
transaction HALO Restricted Stock Units Award $0 +67.5K $0.00 67.5K Feb 16, 2023 Common Stock 67.5K $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported disposition of 11,061 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.
F2 This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
F3 This option vests one-fourth on such date and then 1/48th monthly thereafter.
F4 This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.